Safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma

BACKGROUND: This study assessed the safety, tolerability, pharmacokinetics and pharmacodynamics of the first-in-class dual mammalian target of rapamycin complex (mTORC)1/mTORC2 inhibitor, AZD8055. METHODS: Patients with advanced solid malignancies or lymphomas were recruited into this phase I, open-...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Naing, A, Aghajanian, C, Raymond, E, Olmos, D, Schwartz, G, Oelmann, E, Grinsted, L, Burke, W, Taylor, R, Kaye, S, Kurzrock, R, Banerji, U
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2012
Assuntos:
Translational Therapeutics
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3461162/
https://ncbi.nlm.nih.gov/pubmed/22935583
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2012.368
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados